Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04202757
Other study ID # NeurologyCenter
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date September 24, 2018
Est. completion date August 8, 2019

Study information

Verified date May 2024
Source The Neurology Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will do a preliminary evaluation of a possible treatment for mild-to-moderate Parkinson's disease. Patients will be treated with either transfusions of plasma from young donors. or with placebo transfusions. In the following several months, Parkinson's symptoms will be monitored and compared for the two groups.


Description:

This is a double-blind placebo controlled trial, designed to evaluate the efficacy of plasma from volunteer donors of ages 18-25. This young fresh frozen plasma (yFFP) will be given intravenously in two doses of 12.5 ml/kg each, with 40-56 hours between doses. In the following 24 weeks, Parkinson's symptoms will be monitored using the short version of the Stanford Presenteeism Scale (SPS-6), and a modified version of the UPDRS scale.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date August 8, 2019
Est. primary completion date August 7, 2019
Accepts healthy volunteers No
Gender All
Age group 45 Years to 90 Years
Eligibility Inclusion Criteria: - Diagnosis of Parkinson's disease - Disease duration of 1 to 5 years - Willingness to confirm the use of adequate birth control while on the trial will be required in premenopausal women without evidence for an inability to become pregnant. - Willingness to not start any other treatment for Parkinson's or Multiple Sclerosis during the parallel part of the trial. Exclusion Criteria: - Other significant disease, which in the view of the study doctor may make assessment of the efficacy of yFFP difficult. - Unstable medical conditions. - Must weigh at least 45.5 kg. Cannot weigh more than 130 kg. - A severe disease state diagnosis - Litigation. Patients in litigation will be excluded only if conclusion of that litigation is imminent during the course of the study. - If patient is pregnant or breastfeeding. - Complete IgA deficiency. - Rare contraindications to yFFP therapy as per summary of product characteristics. - Receiving yFFP for other reasons. - Ongoing drug or alcohol abuse. - Psychiatric disorder that could, in the judgement of the site investigator, interfere with successful study participation. - Unwillingness or inability to complete the study or an inability to understand the questionnaires being used. - Cancer other than basal cell carcinoma within the last 5 years. However, those patients who have received definitive treatment, such as curative surgery more than 6 months ago, with no known recurrence can be included. - A history of hypercoagulable or thrombophilic clotting abnormalities. - A history of thromboembolic events: ischaemic stroke, confirmed myocardial infarction, pulmonary embolism; deep venous thrombosis except where immobility related (for example, after injury or operation). - Unstable angina pectoris. - Medications that might react with yFFP such as blood thinners - Renal failure or serum creatinine greater than 1.5 times the upper limit of normal at screening. - Any medical condition that, in the opinion of the investigator, would make it unsafe for the patient to participate or which would interfere with assessment of the outcome measures. - Participation in another interventional trial within 3 months of randomization. Participation in non-interventional studies is not a reason for exclusion.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
[21CFR640.30] Plasma from 18 - 25 year old volunteer donors
12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
Other:
Saline
12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.

Locations

Country Name City State
United States The Neurology Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
The Neurology Center Carolina Longevity Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Physician assessment Unified Parkinson Disease Rating Scale (UPDRS) Two weeks prior to infusion, at one-three-six months post-infusion
Primary Patient assessment Changes in Stanford Presenteeism Scale (SPS) Two weeks prior to infusion, at one-three-six months post-infusion
Secondary Stability of administration Adverse events (if any) At the time of infusions, day 1 and day 2
Secondary Factors predicting a beneficial response Patient Global Impression of change After the last participant's final contact at 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05103618 - Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA Phase 2
Completed NCT03700684 - Voice Treatment for Parkinson's Disease N/A
Completed NCT05027620 - Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology N/A
Completed NCT03652363 - GDNF in ideopathicParkinsons Disease Phase 2
Recruiting NCT02960464 - tDCS for Treatment of Depression in Parkinson's Disease N/A
Completed NCT05699161 - Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson Phase 1/Phase 2
Completed NCT03944785 - Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Terminated NCT01215227 - An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) Phase 3
Withdrawn NCT05832775 - Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's Phase 1
Active, not recruiting NCT02780895 - Parkinsonian Brain Repair Using Human Stem Cells Phase 1
Recruiting NCT01860794 - Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease Phase 1/Phase 2
Completed NCT02373072 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease Phase 1
Terminated NCT02393027 - Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999 Early Phase 1
Completed NCT02445651 - Physiological Effects of Nutritional Support in Patients With Parkinson's Disease N/A
Completed NCT00437125 - Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease Phase 4
Completed NCT02723396 - Sleep, Awake & Move - Part I
Completed NCT00599339 - Transdermal Rotigotine User Surveillance Study
Suspended NCT05471609 - Sustained Release Oral Formulation for Treatment of Parkinson's Disease Early Phase 1
Completed NCT00160576 - Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias Phase 2